Understanding the Evolving Perspectives of Patient Advocacy Groups and Their Role in Drug Development
The Rare Advocacy Movement partnered with Covance to gain a better understanding of the evolving perspectives of patient advocacy groups (PAG's) and the various roles PAG's see themselves serving in the drug development continuum.
In order to generate data to inform public discussions and to find ways to better embed the critical pulse of the patient community throughout the drug development continuum, a survey was developed, of which the insights were presented at the WODC in April of 2019 and utilized to develop the rare360 program.
presented at the World Orphan Drug Congress (WODC) in Washington D.C.,
Covance Inc., the drug development business of LabCorp®, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®.